Exagen Inc.: ASP Challenges, Margin Impact, and Valuation Outlook

Based on my comprehensive analysis of Exagen Inc. (Nasdaq: XGN) and the autoimmune diagnostics market, I can provide a detailed assessment of how ASP challenges may impact the company’s profit margins and valuation trajectory.

---

Exagen Inc., a leading provider of autoimmune diagnostic testing focused on the AVISE® CTD platform, faces nuanced ASP (Average Selling Price) dynamics that present both opportunities and risks to its profit margins and valuation. Despite ASP “headwinds” noted in H2 2025, the company has demonstrated remarkable resilience, achieving record preliminary 2025 revenue of $66-67 million (19-20% YoY growth) with trailing twelve-month ASP expansion to $441-445. The fundamental question remains: can Exagen navigate pricing pressures while sustaining its growth trajectory in the expanding autoimmune diagnostics market?[0][1]

---

Exagen has demonstrated substantial ASP growth over the past two years:

Period	TTM ASP	YoY Growth	Quarter-over-Quarter
Q1 2024	$377	—	+$8
Q2 2024	$385	+$8	+$2
Q3 2024	$392	+$15	+$7
Q4 2024	$400	+$23	+$8
Q1 2025	$419	+$42	+$19
Q2 2025	$435	+$50	+$16
Q3 2025	$440	+$48	+$5
Q4 2025 (Est.)	$443	+$43	+$3

The deceleration in ASP growth during H2 2025 is notable: Q3 2025 added only $5 to the TTM ASP versus $16 in Q2 2025, representing a

. This “headwind” prompted management commentary and has implications for margin sustainability.[0][2]

Several factors contribute to the ASP challenges:

• Commercial payors (54.8% of Q3 2025 revenue) provide higher ASP with better margins
• Government payors (23.1%) exert downward pressure with Medicare rate limitations
• Client Direct Bill (21.6%) carries variable ASP based on negotiated contracts
• Government mix expansion would compress overall ASP[2]

• Consistent commercial payor claim denials due to unfavorable medical policies
• AVISE® Lupus Local Coverage Determination (LCD) pending with CMS/MolDX program
• January 2025 Regulatory Freeze Pending Review Executive Order created LCD timing uncertainty
• Commercial payors have historically reduced reimbursements and sought recovery of perceived overpayments[2]

• Multiplex immunoassay market expanding with new entrants
• Germany and other European markets implementing reimbursement for rheumatoid arthritis panels
• Potential for increased competition in the $5.57 billion (2025) autoimmune diagnostics market[3][4]

---

Despite ASP challenges, Exagen has maintained gross margin improvement:

Quarter	Gross Margin	YoY Change	Comment
Q3 2024	55.8%	—	Baseline
Q4 2024	59.6%	+3.8pp	Strong ASP growth
Q1 2025	58.9%	+3.3pp	Maintained elevated level
Q2 2025	60.4%	+4.6pp	Peak margin quarter
Q3 2025	58.4%	+2.6pp	ASP headwinds evident

The

demonstrates the direct impact of ASP deceleration on gross margins. With Q3 2025 revenue of $17.24 million, each percentage point of gross margin represents approximately $172,400 in gross profit impact.[0][2]

1. New Biomarker Launches:
   January 2025 SLE/RA biomarker and September 2025 PAD4 biomarker assays support premium pricing
2. Volume Growth:
   AVISE CTD test volume increased 16% YoY in Q3 2025, providing overhead absorption benefits
3. Revenue Cycle Optimization:
   Claim withholding, appeals efforts, and patient payment rate increases improving collections

1. Cost Inflation:
   Materials/supplies costs for new biomarkers increasing
2. Higher Employee-Related Expenses:
   Salesforce expansion and infrastructure investments
3. Facility Costs:
   Operating lease and facility-related expenses
4. Tariff Risk:
   Potential U.S. trade policy changes could increase costs for imported reagents from Germany[2]

Exagen’s operating structure presents challenges:

Metric	Q3 2025	Q3 2024	Change
Revenue	$17,244K	$12,507K	+37.9%
Operating Expenses	$13,175K	$11,644K	+13.1%
Operating Loss	$(3,100K)	$(4,663K)	Improved
Operating Margin	-18.0%	-37.3%	+19.3pp

The operating expense ratio of

indicates significant operating leverage potential as revenue scales. Management expects SG&A expenses to “increase moderately in absolute dollars but decrease as a percentage of revenue,” while R&D expenses “stay flat or decrease as a percentage of revenue.”[2]

---

Metric	Value	Industry Comparison
Market Cap	$143.68M	Small-cap diagnostic
Current Price	$6.34	—
P/E Ratio	-7.61x	N/A (unprofitable)
P/B Ratio	7.99x	Elevated
EV/OCF	-13.29x	Negative cash flow
analyst Consensus	BUY	8 of 8 analysts
Price Target	$15.00	+136.6% upside

Canaccord Genuity and other analysts maintain Buy ratings despite ASP challenges, with consensus price targets suggesting

from current levels. Key bullish thesis elements include:

1. Market Growth Tailwinds:
   Autoimmune diagnostics market projected to grow from $5.57B (2025) to $8.98B (2031) at 8.3% CAGR
2. Product Innovation:
   New biomarker assays expanding clinical utility and pricing power
3. Volume Growth Trajectory:
   11% test volume growth (136,000-137,000 tests in 2025) supporting revenue scale
4. Path to Profitability:
   Operating leverage from fixed cost base as revenue grows[0][3][4]

The relationship between ASP and valuation is complex:

• Sustained gross margin above 60%
• Faster path to operating profitability
• Higher multiple justified by growth quality
• Implies price target achievement

• Gross margin compression to 55-57%
• Extended timeline to profitability
• Multiple compression as growth slows
• Price target risk of 20-30%

• Margin erosion to 50-53%
• Potential need for strategic alternatives
• Significant multiple compression
• Value destruction risk

1. Medicare Coverage Decision:
   AVISE® Lupus LCD approval would unlock significant revenue potential and validate clinical utility
2. Commercial Payor Expansion:
   Additional managed care medical policy wins would strengthen ASP trajectory
3. Biopharma Collaborations:
   Strategic partnerships could provide non-dilutive funding and validation
4. Operating Leverage:
   Revenue growth outpacing expense growth would demonstrate scalable model[2]

---

The autoimmune diagnostics market presents a favorable backdrop:

Market Segment	2025 Share	Growth Rate
Systemic Autoimmune Diseases	66.73%	High single-digit CAGR
Consumables/Assays	70.43%	Recurring revenue
Immunoassays	31.48%	Technology leader
Hospitals/Clinics	44.46%	Primary end user

• Specialized focus on rheumatology with deep clinical expertise
• AVISE® CTD platform with unique biomarker offerings (SLE, RA, PAD4)
• Established relationships with rheumatologists and their practices
• Strong clinical validation supporting reimbursement efforts

• Dependence on payer reimbursement policies
• Small scale relative to large diagnostic laboratories
• Limited geographic diversification (U.S.-focused)
• Concentration risk (Customer A: 24%, Customer B: 21% of revenue)

1. Large Laboratory Entrants:
   Quest, Labcorp could expand autoimmune testing offerings
2. International Competition:
   European multiplex panel adoption increasing competitive pressure
3. Technology Disruption:
   AI-enabled pattern recognition and POC testing advances
4. Pricing Pressure:
   Reimbursement compression across diagnostic industry[3][4]

---

Risk Category	Specific Risk	Impact	Probability
Reimbursement	AVISE® Lupus LCD denial	High	Medium
Pricing	Commercial payor rate cuts	High	High
Competitive	New market entrants	Medium	Medium
Operational	Supply chain/tariff disruption	Medium	Low
Financial	Cash flow sustainability	Medium	Medium

1. Revenue Cycle Optimization:
   Continued investment in appeals and documentation
2. Product Diversification:
   New biomarker pipeline expansion
3. Payer Diversification:
   Reducing concentration in top customers
4. Capital Preservation:
   Careful expense management while investing in growth

• ASP stabilization with continued volume growth
• Medicare coverage decision favorable
• Operating leverage drives profitability by 2027
• Market positioning captures 8.3% CAGR growth
• Implies 200%+ upside from current levels

• ASP growth slows to 3-5% annually
• Gross margins stabilize at 57-59%
• Path to profitability by 2028
• Current price target of $15 achievable

• ASP decline due to payer pressure
• Gross margin compression below 55%
• Competitive losses accelerate
• Strategic alternatives considered
• 50%+ downside from current levels

---

• Near-term (0-12 months):
  Moderate margin pressure expected with gross margins likely in the 56-59% range
• Medium-term (12-24 months):
  Potential stabilization if Medicare coverage obtained and commercial policies expand
• Long-term (24+ months):
  Sustainable margins depend on successful operating leverage and product innovation

• Current:
  ASP headwinds partially priced in, with 136% analyst consensus upside suggesting opportunity
• Near-term:
  Multiple compression unlikely unless ASP decline accelerates
• Medium-term:
  Valuation recovery tied to profitability path and market multiple expansion

Investors should monitor the following indicators:

1. Quarterly ASP Trajectory:
   Sequential ASP growth rate
2. Gross Margin Trend:
   Direction and sustainability
3. Medicare Coverage Status:
   AVISE® Lupus LCD decision timing
4. Commercial Payor Policy Updates:
   New coverage wins
5. Test Volume Growth:
   Indicates market adoption
6. Operating Expense Ratio:
   Measure of operating leverage
7. Cash Burn Rate:
   Path to self-funding

Exagen’s ASP challenges represent a manageable headwind rather than an existential threat to the company’s valuation. The 2.0 percentage point gross margin compression from Q2 to Q3 2025 demonstrates the direct impact of ASP deceleration, but the company’s

, , and indicate underlying business momentum remains intact.

The autoimmune diagnostics market’s favorable growth dynamics (8.3% CAGR through 2031), combined with Exagen’s specialized positioning and product innovation pipeline, provide a foundation for value creation. However, the

and remain critical inflection points that will significantly influence both margin sustainability and valuation trajectory.

For investors, Exagen represents a

in the autoimmune diagnostics space. The ASP challenges are real and material, but they are being actively managed through revenue cycle optimization, product innovation, and strategic payer engagement. The key question is not whether ASP challenges exist—they clearly do—but whether Exagen can navigate these pressures while maintaining the volume growth and operational execution necessary to achieve sustainable profitability.

---

[0] Quiver Quantitative - Exagen Inc. Reports Preliminary Financial Results for Q4 and Full Year 2025 (https://www.quiverquant.com/news/Exagen+Inc.+Reports+Preliminary+Financial+Results+for+Q4+and+Full+Year+2025%2C+Highlighting+Record+Revenue+Growth)

[1] Yahoo Finance - Exagen Inc. Announces Select Preliminary 2025 Financial Results (https://finance.yahoo.com/news/exagen-inc-announces-select-preliminary-200000104.html)

[2] SEC.gov - Exagen Inc. Form 10-Q (Q3 2025) (https://www.sec.gov/Archives/edgar/data/1274737/000127473725000071/exdx-20250930.htm)

[3] ResearchAndMarkets.com - Autoimmune Disease Diagnosis Market (https://finance.yahoo.com/news/autoimmune-disease-diagnosis-market-surge-112800275.html)

[4] Fact.MR - Autoimmune Disease Diagnostics Market Report (https://www.factmr.com/report/autoimmune-disease-diagnostics-market)

[5] Simply Wall St - Exagen Company Analysis (https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xgn/exagen)

[6] Nasdaq/Fintel - Canaccord Genuity Maintains Exagen (XGN) Buy Recommendation (https://www.nasdaq.com/articles/canaccord-genuity-maintains-exagen-xgn-buy-recommendation)